Safeplus International Holdings Limited (ACAI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSafeplus International Holdings Limited (ACAI) trades at $0.0003. Safeplus International Holdings Limited, formerly Biophan Technologies, focuses on developing and marketing medical device technologies. The company seeks partnerships to monetize its patented technologies, including biothermal power and photonics. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for ACAI: ACAI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Safeplus International Holdings Limited (ACAI) Healthcare & Pipeline Overview
Safeplus International Holdings Limited, operating in the financial services sector as a shell company, focuses on developing and marketing medical device technologies. The company seeks partnerships to monetize its patented technologies, including biothermal power supply and pulsewidth modulation technology, primarily targeting the medical device industry.
What Is the Investment Thesis for ACAI?
Safeplus International Holdings Limited presents a speculative investment opportunity due to its focus on monetizing patented medical device technologies. The company's success hinges on securing partnerships to commercialize its biothermal power, pulsewidth modulation, photonics, and nanomaterials patents. Key value drivers include the successful licensing or sale of these patents, which could generate significant revenue. However, the company's small size, limited operating history under the Safeplus name, and OTC listing introduce substantial risks. The negative P/E ratio of -0.27 and a beta of -17.91 highlight the company's current financial instability and high volatility. Growth catalysts depend on the company's ability to attract partners and demonstrate the value of its technologies, while risks include the failure to monetize patents and continued operating losses.
Based on FMP financials and quantitative analysis
ACAI Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -0.27 reflects the company's lack of profitability.
- Beta of -17.91 suggests extremely high volatility compared to the overall market.
- Dividend yield of None indicates that the company does not currently distribute profits to shareholders.
- Focus on patented technologies in the medical device industry provides potential for high-margin revenue streams.
Who Are ACAI's Competitors?
ACAI is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ITOC iTonic Holdings Ltd. | $2.53 | -9.64% | $17.4M | 30 5-pillar |
| QTEX Inspira Technologies Oxy B.H.N. Ltd. | $1.29 | -7.19% | $60.6M | 46 5-pillar |
| SI SHOULDER INNOVATIONS, INC. | $19.38 | -1.42% | $403M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACAI's Key Strengths?
Patented technologies in the medical device industry.
- Potential for high-margin revenue streams.
- Focus on niche technologies.
- Experienced leadership.
What Are ACAI's Weaknesses?
Small size and limited resources.
- Dependence on securing partnerships.
- OTC listing increases risk.
- Negative P/E ratio indicates lack of profitability.
What Are the Key Risks for ACAI?
Negative return on equity (-58.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure partnerships or monetize patents.
- Limited financial resources and small size.
- OTC listing increases risk and volatility.
- Technological obsolescence of patented technologies.
- Competition from larger medical device companies.
What Are ACAI's Competitive Advantages?
- Patented technologies provide a degree of exclusivity.
- Focus on niche technologies in the medical device industry.
- Potential for strong relationships with medical device manufacturers.
What Does ACAI Do?
Safeplus International Holdings Limited, formerly known as Biophan Technologies, Inc., was founded in 1963 and is based in Pittsford, New York. The company underwent a name change in September 2020, signaling a shift in its strategic direction. Safeplus operates within the financial services sector, specifically as a shell company focused on developing and marketing technologies for the medical device industry. Its core business revolves around seeking partners to monetize its portfolio of patented technologies. These technologies include biothermal power supply and pulsewidth modulation technology designed to enhance the performance of pacemakers and neurostimulators. Additionally, the company holds patents in photonics and nanomaterials, further diversifying its technological assets. With a small team of two employees, Safeplus International Holdings Limited concentrates on leveraging its intellectual property to generate revenue through strategic partnerships and licensing agreements within the medical device market.
What Products and Services Does ACAI Offer?
- Develops and markets technologies for the medical device industry.
- Seeks partners to monetize patented technologies.
- Focuses on biothermal power supply technology.
- Develops pulsewidth modulation technology.
- Holds patents in photonics and nanomaterials.
- Aims to enhance the performance of pacemakers and neurostimulators.
How Does ACAI Make Money?
- Monetizes patented technologies through licensing agreements.
- Generates revenue through strategic partnerships.
- Potentially generates revenue through the sale of patents.
What Industry Does ACAI Operate In?
Safeplus International Holdings Limited operates within the financial services sector as a shell company targeting the medical device industry. The medical device market is characterized by rapid technological advancements and stringent regulatory requirements. Companies like Safeplus seek to capitalize on niche technologies and form partnerships with established medical device manufacturers. The competitive landscape includes both large, diversified medical technology companies and smaller, specialized firms. The company's success depends on its ability to differentiate its patented technologies and navigate the complex regulatory environment.
Who Are ACAI's Key Customers?
- Medical device manufacturers seeking innovative technologies.
- Companies interested in licensing patented technologies.
- Potential acquirers of the company's intellectual property.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Safeplus International Holdings Limited operates in the Healthcare sector. It is headquartered in Pittsford, US. ACAI has traded publicly since 2002.
Key Financial Metrics
Return on equity for Safeplus International Holdings Limited stands at -58.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.7%, showing how much profit it generates from its asset base. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Safeplus International Holdings Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ACAI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ACAI Latest News
No recent news available for ACAI.
ACAI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ACAI.
Price Targets
Wall Street price target analysis for ACAI.
ACAI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ACAI; grades run from A+ (80-100) to F (below 30).
Leadership: Margaret V. Russell
CEO
Margaret V. Russell serves as the CEO of Safeplus International Holdings Limited, managing a small team of two employees. As CEO, she is responsible for guiding the company's strategic direction, securing partnerships, and overseeing the monetization of its patented technologies in the medical device industry. Her leadership is crucial to the company's success in a competitive and rapidly evolving market.
Track Record: Due to the limited information available, it is not possible to assess Margaret V. Russell's track record at Safeplus International Holdings Limited. The company's performance under her leadership will be a key indicator of her effectiveness as CEO. Investors should monitor the company's progress in securing partnerships, generating revenue, and achieving profitability to evaluate her performance.
ACAI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Safeplus International Holdings Limited may not meet minimum financial standards or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial disclosures, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosures increase the risk of investing in ACAI.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for price manipulation due to lack of regulatory oversight.
- Higher risk of fraud compared to companies listed on major exchanges.
- Limited access to information about the company's operations and financial performance.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and announcements for any red flags.
- Company has been in business since 1963.
- Focus on developing patented technologies.
- Seeking partnerships to monetize its intellectual property.
- Company headquarters located in Pittsford, New York.
- Company changed name in 2020.
ACAI Healthcare Stock FAQ
What do analysts say about ACAI stock?
Currently, there is no available analyst coverage for Safeplus International Holdings Limited (ACAI). This lack of coverage is typical for companies trading on the OTC Other tier, which often have limited financial disclosures and low trading volume. Investors should conduct their own thorough due diligence and carefully consider the risks before investing in ACAI.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing increases risk and uncertainty.
- Lack of analyst coverage.